David Belada

7.8k total citations
167 papers, 1.1k citations indexed

About

David Belada is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, David Belada has authored 167 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 146 papers in Pathology and Forensic Medicine, 87 papers in Genetics and 71 papers in Oncology. Recurrent topics in David Belada's work include Lymphoma Diagnosis and Treatment (146 papers), Chronic Lymphocytic Leukemia Research (85 papers) and CAR-T cell therapy research (31 papers). David Belada is often cited by papers focused on Lymphoma Diagnosis and Treatment (146 papers), Chronic Lymphocytic Leukemia Research (85 papers) and CAR-T cell therapy research (31 papers). David Belada collaborates with scholars based in Czechia, United States and Spain. David Belada's co-authors include Marek Trněný, Andrea Janíková, Robert Pytlík, Heidi Móciková, Vít Procházka, Lukáš Smolej, Vít Campr, Martin Šimkovič, Jiří Mayer and Jiřı́ Mayer and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

David Belada

150 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Belada Czechia 18 819 604 327 176 175 167 1.1k
F. Morschhauser France 13 693 0.8× 449 0.7× 182 0.6× 168 1.0× 166 0.9× 27 944
Masahiro Yokoyama Japan 15 575 0.7× 461 0.8× 325 1.0× 185 1.1× 104 0.6× 61 1.0k
Manali Kamdar United States 17 818 1.0× 1.1k 1.7× 286 0.9× 211 1.2× 145 0.8× 90 1.4k
Sophie Lefort France 6 994 1.2× 698 1.2× 352 1.1× 167 0.9× 283 1.6× 10 1.3k
Jamie Hirata United States 17 1.1k 1.3× 1.0k 1.7× 425 1.3× 215 1.2× 159 0.9× 64 1.4k
Celeste Bello United States 13 808 1.0× 544 0.9× 640 2.0× 247 1.4× 142 0.8× 63 1.3k
Andrew Haynes United Kingdom 15 1.0k 1.3× 516 0.9× 655 2.0× 370 2.1× 120 0.7× 36 1.3k
Michelle Byrtek United States 12 964 1.2× 847 1.4× 316 1.0× 95 0.5× 161 0.9× 29 1.1k
P. Solal-Céligny France 8 1.2k 1.5× 818 1.4× 539 1.6× 155 0.9× 389 2.2× 14 1.5k
Roswitha Forstpointner Germany 15 1.5k 1.8× 1.1k 1.9× 732 2.2× 182 1.0× 188 1.1× 38 1.7k

Countries citing papers authored by David Belada

Since Specialization
Citations

This map shows the geographic impact of David Belada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Belada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Belada more than expected).

Fields of papers citing papers by David Belada

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Belada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Belada. The network helps show where David Belada may publish in the future.

Co-authorship network of co-authors of David Belada

This figure shows the co-authorship network connecting the top 25 collaborators of David Belada. A scholar is included among the top collaborators of David Belada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Belada. David Belada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Michael, Wojciech Jurczak, Marek Trněný, et al.. (2025). Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. The Lancet Oncology. 26(2). 200–213. 9 indexed citations
2.
Morschhauser, Franck, David Belada, Johannes Duell, et al.. (2024). Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma. Blood. 144(Supplement 1). 867–867. 4 indexed citations
3.
Brody, Joshua, David Belada, Régis Costello, et al.. (2024). Subcutaneous epcoritamab + GemOx in patients with relapsed or refractory DLBCL: Updated results from EPCORE NHL-2.. Journal of Clinical Oncology. 42(16_suppl). 7037–7037. 3 indexed citations
4.
Falchi, Lorenzo, Joost S.P. Vermaat, Gerardo Musuraca, et al.. (2024). IBCL-278 Epcoritamab With Rituximab + Lenalidomide (R2) in Previously Untreated (1L) Follicular Lymphoma (FL) and Epcoritamab Maintenance Therapy in FL: EPCORE NHL-2 Arms 6 and 7. Clinical Lymphoma Myeloma & Leukemia. 24. S496–S497. 1 indexed citations
5.
Wang, Michael, Wojciech Jurczak, Marek Trněný, et al.. (2024). Efficacy and safety of ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) and TP53 mutations in the SYMPATICO study.. Journal of Clinical Oncology. 42(16_suppl). 7007–7007. 4 indexed citations
6.
Jurczak, Wojciech, Michael Wang, Marek Trněný, et al.. (2024). Efficacy and Safety of Ibrutinib Plus Venetoclax in Patients With Mantle Cell Lymphoma (MCL) and TP53 Mutations in the SYMPATICO Study. Clinical Lymphoma Myeloma & Leukemia. 24. S226–S226.
7.
Trněný, Marek, Abraham Avigdor, Matthew McKinney, et al.. (2023). Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study. EClinicalMedicine. 63. 102130–102130. 3 indexed citations
8.
Wang, Michael, Wojciech Jurczak, Marek Trněný, et al.. (2023). Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study. Blood. 142(Supplement 2). LBA–2. 13 indexed citations
9.
Falchi, Lorenzo, Michael Roost Clausen, Fritz Offner, et al.. (2023). HIGH COMPLETE METABOLIC RESPONSE RATES WITH EPCORITAMAB + R‐CHOP IN PREVIOUSLY UNTREATED (1L) HIGH‐RISK DLBCL, INCLUDING DOUBLE‐HIT/TRIPLE‐HIT: EPCORE NHL‐2 UPDATE. Hematological Oncology. 41(S2). 207–208. 2 indexed citations
10.
Belada, David, Kateřina Kopečková, Juan Bergua, et al.. (2023). Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study. Blood. 142(16). 1348–1358. 12 indexed citations
11.
Šimkovič, Martin, et al.. (2020). Rituximab, Cyclophosphamide and Dexamethasone (RCD) Chemoimmunotherapy for Relapsed Chronic Lymphocytic Leukaemia. European Journal of Clinical Investigation. 51(4). e13421–e13421.
12.
Belada, David, et al.. (2017). Refractory mantle cell lymphoma in elderly patient - case report. 11(3). 149–153.
13.
Arcaini, Luca, Thierry Lamy, Jan Walewski, et al.. (2017). Prospective subgroup analyses of the randomized MCL‐002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma. British Journal of Haematology. 180(2). 224–235. 9 indexed citations
14.
Trotman, Judith, Sally F. Barrington, David Belada, et al.. (2017). Comparison Of Contrast-Enhanced Ct-Based Response With Pet Assessment After First-Line Therapy For Follicular Lymphoma In The Phase Iii Gallium Study. Haematologica. 1 indexed citations
15.
Kostakoglu, Lale, Maurizio Martelli, Laurie H. Sehn, et al.. (2017). Baseline PET-Derived Metabolic Tumor Volume Metrics Predict Progression-Free and Overall Survival in DLBCL after First-Line Treatment: Results from the Phase 3 GOYA Study. Blood. 130(Suppl_1). 824–824. 20 indexed citations
16.
Arcaini, Luca, Jan Walewski, A B Skotnicki, et al.. (2015). QUALITY OF LIFE IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS TREATED WITH LENALIDOMIDE VS INVESTIGATOR'S CHOICE: MCL-002 (SPRINT) TRIAL. Haematologica. 2 indexed citations
17.
Trněný, Marek, Jan Walewski, David Belada, et al.. (2015). IMPACT OF PRIOR TREATMENT ON PFS FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS RANDOMIZED TO LENALIDOMIDE VS INVESTIGATOR'S CHOICE: A SUBGROUP ANALYSIS OF THE PHASE II MCL-002 (SPRINT) STUDY. Haematologica. 100(4). 2 indexed citations
18.
Adam, Zdeněk, Roman Hájek, Marta Krejčí, et al.. (2014). Diagnostika a léčba Waldenströmovy makroglobulinemie. 20.
19.
Belada, David, et al.. (2010). Diffuse large B-cell lymphoma in a patient with hyper-IgEsyndrome: Successful treatment with risk-adaptedrituximab-based immunochemotherapy. Leukemia Research. 2 indexed citations
20.
Belada, David, et al.. (2003). Intravascular Large B-Cell Lymphoma Presenting As Cutaneous Panniculitis. Acta Medica (Hradec Kralove Czech Republic). 46(3). 121–123. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by F. Morschhauser Breakdown of academic impact, for papers by Masahiro Yokoyama Breakdown of academic impact, for papers by Manali Kamdar Breakdown of academic impact, for papers by Sophie Lefort Breakdown of academic impact, for papers by Jamie Hirata Breakdown of academic impact, for papers by Celeste Bello Breakdown of academic impact, for papers by Andrew Haynes Breakdown of academic impact, for papers by Michelle Byrtek Breakdown of academic impact, for papers by P. Solal-Céligny Breakdown of academic impact, for papers by Roswitha Forstpointner
Rankless by CCL
2026